"Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where Are We Now?"

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2023 Aug 3

PMID 37533589

Authors

Anna Holler

Bich Doan Nguyen-Strauli

Heike Frauchiger-Heuer

Alexander Ring

Affiliations

Soon will be listed here.

Abstract

Luminal breast cancers are hormone receptor (estrogen and/or progesterone) positive that are further divided into HER2-negative luminal A and HER2-positive luminal B subtypes. According to currently accepted convention, they represent the most common subtypes of breast cancer, accounting for approximately 70% of cases. Biomarkers play a critical role in the functional characterization, prognostication, and therapeutic prediction, rendering them indispensable for the clinical management of invasive breast cancer. Traditional biomarkers include clinicopathological parameters, which are increasingly extended by genetic and other molecular markers, enabling the comprehensive characterization of patients with luminal breast cancer. Liquid biopsies capturing and analyzing circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are emerging technologies that envision personalized management through precision oncology. This article reviews key biomarkers in luminal breast cancer and ongoing developments.

Citing Articles

Palbociclib as an Antitumor Drug: A License to Kill.

Lupicka-Slowik A, Cossu F, Sienczyk M Molecules. 2024; 29(22).

PMID: 39598723 PMC: 11596203. DOI: 10.3390/molecules29225334.

Combining Molecular and Traditional Prognostic Factors: A Holistic Approach to Breast Cancer Prognostication.

Moraru L, Mitranovici M, Moraru R, Voidazan S, Munteanu M, Georgescu R Diagnostics (Basel). 2024; 14(13).

PMID: 39001339 PMC: 11241232. DOI: 10.3390/diagnostics14131449.

The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.

Olbromski M, Mrozowska M, Piotrowska A, Smolarz B, Romanowicz H Cancer Immunol Immunother. 2024; 73(8):136.

PMID: 38833004 PMC: 11150347. DOI: 10.1007/s00262-024-03701-w.

Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells.

Kotsifaki A, Maroulaki S, Armakolas A Int J Mol Sci. 2024; 25(9).

PMID: 38732051 PMC: 11084220. DOI: 10.3390/ijms25094832.

Tamoxifen Activates Transcription Factor EB and Triggers Protective Autophagy in Breast Cancer Cells by Inducing Lysosomal Calcium Release: A Gateway to the Onset of Endocrine Resistance.

Boretto C, Actis C, Faris P, Cordero F, Beccuti M, Ferrero G Int J Mol Sci. 2024; 25(1).

PMID: 38203629 PMC: 10779225. DOI: 10.3390/ijms25010458.

References

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Andrade de Oliveira K, Sengupta S, Yadav A, Clarke R . The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness. Front Endocrinol (Lausanne). 2023; 14:1083048. PMC: 9997040. DOI: 10.3389/fendo.2023.1083048. View

Pegram M, Jackisch C, Johnston S . Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. NPJ Breast Cancer. 2023; 9(1):45. PMC: 10232442. DOI: 10.1038/s41523-023-00533-2. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Hamam R, Hamam D, Alsaleh K, Kassem M, Zaher W, Alfayez M . Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis. 2017; 8(9):e3045. PMC: 5636984. DOI: 10.1038/cddis.2017.440. View

Sledge Jr G, Toi M, Neven P, Sohn J, Inoue K, Pivot X . The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019; 6(1):116-124. PMC: 6777264. DOI: 10.1001/jamaoncol.2019.4782. View

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

10.

Ignatiadis M, Litiere S, Rothe F, Riethdorf S, Proudhon C, Fehm T . Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. Ann Oncol. 2018; 29(8):1777-1783. DOI: 10.1093/annonc/mdy211. View

11.

Kodahl A, Ehmsen S, Pallisgaard N, Jylling A, Jensen J, Laenkholm A . Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer. Mol Oncol. 2018; 12(6):925-935. PMC: 5983134. DOI: 10.1002/1878-0261.12305. View

12.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

13.

Cottu P, DHondt V, Dureau S, Lerebours F, Desmoulins I, Heudel P . Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018; 29(12):2334-2340. DOI: 10.1093/annonc/mdy448. View

14.

Alix-Panabieres C, Pantel K . Liquid Biopsy: From Discovery to Clinical Application. Cancer Discov. 2021; 11(4):858-873. DOI: 10.1158/2159-8290.CD-20-1311. View

15.

Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M . Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010; 16(9):2634-45. DOI: 10.1158/1078-0432.CCR-09-2042. View

16.

Trenner A, Sartori A . Harnessing DNA Double-Strand Break Repair for Cancer Treatment. Front Oncol. 2020; 9:1388. PMC: 6921965. DOI: 10.3389/fonc.2019.01388. View

17.

Toft D, Shyamala G, Gorski J . A receptor molecule for estrogens: studies using a cell-free system. Proc Natl Acad Sci U S A. 1967; 57(6):1740-3. PMC: 224541. DOI: 10.1073/pnas.57.6.1740. View

18.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

19.

Martinez-Jimenez F, Movasati A, Brunner S, Nguyen L, Priestley P, Cuppen E . Pan-cancer whole-genome comparison of primary and metastatic solid tumours. Nature. 2023; 618(7964):333-341. PMC: 10247378. DOI: 10.1038/s41586-023-06054-z. View

20.

Park S, Nam J . The force awakens: metastatic dormant cancer cells. Exp Mol Med. 2020; 52(4):569-581. PMC: 7210927. DOI: 10.1038/s12276-020-0423-z. View